Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

66.94 -0.11 (-0.16%)
Streaming Delayed Price Updated: 11:49 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 159,586
Open 67.05
Bid (Size) 66.93 (2)
Ask (Size) 66.95 (1)
Prev. Close 67.05
Today's Range 66.92 - 67.12
52wk Range 47.59 - 69.68
Shares Outstanding 46,134,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolization. Potential adverse effects include bowel ischemia, necessitating major... 
Via Benzinga
Exposures Product Safety
Axonics Stockholders Approve Merger Agreement with Boston Scientific
From Axonics, Inc.
Via Business Wire

Performance

YTD
+12.11%
+12.11%
1 Month
-2.56%
-2.56%
3 Month
-2.03%
-2.03%
6 Month
+28.46%
+28.46%
1 Year
+13.15%
+13.15%

More News

Read More
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics Responds to ITC Action by Medtronic
From Axonics, Inc.
Via Business Wire
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Via Benzinga
Analyst Scoreboard: 5 Ratings For Axonics
Via Benzinga
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Axonics, Inc.
Via Business Wire
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
From Kahn Swick & Foti, LLC
Via Business Wire
Why Medical Devices Giant Boston Scientific Shares Are Rising Today
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Axonics Stock Soared Today
Via The Motley Fool
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
Via Investor's Business Daily
Topics ETFs
Robinhood, Palo Alto Networks And 2 Other Stocks Insiders Are Selling
Via Benzinga
10 Top Stocks With a Strong Buy Rating Right Now
Via InvestorPlace
Health Care Company Boston Scientific Announces Acquisition of Axonics
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Is Crocs (CROX) Stock Up 20% Today?
Via InvestorPlace
Why Is Axonics (AXNX) Stock Up 20% Today?
Via InvestorPlace
Why Is Bladder Disorder Focused Axonics Stock Trading Higher Today?
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
Via Investor's Business Daily
AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
From Axonics, Inc.
Via Business Wire
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
From Axonics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.